Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies.
Saved in:
| Title: | Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies. |
|---|---|
| Authors: | Miller MJ; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, CA 91320, United States of America. Electronic address: millermj@amgen.com., Kroenke MA; Clinical Immunology, Amgen, Thousand Oaks, CA 91320, United States of America., Barger T; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, CA 91320, United States of America., Manning MS; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, CA 91320, United States of America., Sohn W; Clinical Pharmacology Modeling and Simulation, Amgen, Thousand Oaks, CA 91320, United States of America., Graham K; Large Molecule Discovery & Research Data Science, Amgen, Thousand Oaks, CA 91320, United States of America., Mytych DT; Clinical Immunology, Amgen, Thousand Oaks, CA 91320, United States of America., Gupta S; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, CA 91320, United States of America. |
| Source: | Journal of immunological methods [J Immunol Methods] 2025 May; Vol. 540, pp. 113864. Date of Electronic Publication: 2025 Apr 10. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1305440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7905 (Electronic) Linking ISSN: 00221759 NLM ISO Abbreviation: J Immunol Methods Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
